Unique Structure Of Geron Corporation’s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity In Lung Cancer Cells

February 15, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti-tumor and anti-metastatic activity.

Twitter
LinkedIn
Facebook
Email
Print

Preclinical